Description
The debate highlighted the lack of evidence for selective small molecule binding between APOE isoforms, combined with blood-brain barrier penetration challenges. This dual requirement of selectivity and CNS access represents a critical druggability question for APOE4-targeted therapeutics.
Source: Debate session sess_SDA-2026-04-01-gap-010 (Analysis: SDA-2026-04-01-gap-010)